Share Twitter LinkedIn Facebook Email Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses.
Understanding and Managing BPDCN: Insights from Priyanka Meta’s Conference Presentation Other 2 Mins Read
Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission [ASH 2023] Other 1 Min Read